- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Infarct size of fibrocytes to increase risk of heart attack
Overview
According to a study in American Heart Journal Circulating fibrocytes measured 6 months after STEMI positively correlate with 6-month infarct size assessed by cardiac magnetic resonance imaging. Fibrocytes have been shown to home to the injured myocardium in patients with myocardial infarction, and the concentration of circulating fibrocytes is a serious risk factor that has to be considered.
Heart attack is classically is characterized by ST-segment elevation myocardial infarction (STEMI). It is one type of myocardial infarction in which a part of the heart muscle (myocardium) has died due to the obstruction of blood supply to the area. Infarct size is a strong predictor of outcomes after ST elevation myocardial infarction. Circulating fibrocytes are bone marrow-derived progenitor cells associated with fibrotic processes.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)